NEW YORK--(BUSINESS WIRE)---- $JSPR #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgi ...

Core Viewpoint - A securities class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly making false and misleading statements regarding its manufacturing processes and the prospects of its products, particularly briquilimab [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of individuals or entities that purchased Jasper securities between November 30, 2023, and July 3, 2025 [1]. - The complaint alleges that Jasper lacked necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results [2]. Group 2: Allegations Against the Company - The failure to ensure compliance with manufacturing regulations increased the risk of confounding study results, adversely affecting the regulatory and commercial prospects of Jasper's products [2]. - The allegations suggest that the company's business and financial prospects, as well as the clinical and commercial prospects of briquilimab, were overstated [2]. - As a result of these issues, the public statements made by the defendants were materially false and misleading throughout the relevant period [2]. Group 3: Investor Information - Investors who acquired shares of Jasper are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on November 18, 2025 [3].

Core Points - A shareholder class action lawsuit has been filed against Jasper Therapeutics, Inc. alleging materially false and misleading statements regarding the company's business and compliance policies [1] - The lawsuit claims that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its product briquilimab [1] - The allegations suggest that Jasper's business and financial prospects, as well as briquilimab's clinical and commercial prospects, were overstated [1] Legal Context - Shareholders who purchased Jasper shares between November 30, 2023, and July 3, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request lead plaintiff status in the lawsuit is November 18, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

Core Viewpoint - Investors in Jasper Therapeutics, Inc. have the opportunity to lead a securities fraud lawsuit against the company with the Schall Law Firm [1] Group 1 - The lawsuit is centered around allegations of securities fraud involving Jasper Therapeutics, Inc. [1] - The Schall Law Firm is actively seeking investors to participate in the lawsuit [1]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of Jasper Therapeutics, Inc. during the specified Class Period from November 30, 2023, to July 3, 2025, due to alleged misleading statements and failures to disclose critical information [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Jasper Therapeutics lacked necessary controls and procedures for third-party manufacturers, which could lead to non-compliance with cGMP regulations [5]. - It is alleged that this failure increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of Jasper's products, particularly briquilimab [5]. - The lawsuit asserts that Jasper's business and financial prospects were overstated, and public statements made by the defendants were materially false and misleading [5]. Group 2: Class Action Participation - Investors who purchased Jasper Therapeutics securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 18, 2025, to represent the interests of other class members in the litigation [1][3]. Group 3: Rosen Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability and experience in handling such cases [4].

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR), between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period†). Jasper is a clinical-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigat. ...

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, briquilimab [1][2]. Group 1: Allegations - The lawsuit claims that Jasper Therapeutics failed to disclose critical information about its manufacturing controls and procedures, which were necessary to ensure compliance with cGMP regulations [2]. - The lack of proper controls increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, including briquilimab [2]. - This situation heightened the likelihood of disruptive cost-reduction measures, leading to an overstatement of the company's business and financial prospects [2]. Group 2: Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decline, closing at $3.04 per share [3]. Group 3: Class Action Participation - Shareholders who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible to participate in the class action [1][4]. - Interested shareholders can contact Robbins LLP to serve as lead plaintiff or remain as absent class members without participating in the case [4].

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - AGM Group Holdings Inc. (AGMH) increased by 185% to $6.36 [3] - AlphaVest Acquisition Corp (ATMV) rose by 77% to $26.80 [3] - Brera Holdings PLC (BREA) saw a 20% increase to $30.00 [3] - Asset Entities Inc. (ASST) gained 18% to $4.54 [3] - 22nd Century Group, Inc. (XXII) also increased by 18% to $2.08 [3] - Millennium Group International Holdings Limited (MGIH) rose by 16% to $2.84 [3] - Robo.ai Inc. (AIIO) increased by 11% to $2.17 [3] - Butterfly Network, Inc. (BFLY) saw a 10% rise to $2.10 [3] - GrafTech International Ltd. (EAF) increased by 9% to $13.91 [3] - Cardlytics, Inc. (CDLX) rose by 8% to $2.99 [3] Premarket Losers - ECD Automotive Design, Inc. (ECDA) decreased by 14% to $3.70 [4] - Champions Oncology, Inc. (CSBR) fell by 8% to $6.11 [4] - Beam Global (BEEM) saw an 8% decline to $2.79 [4] - Fathom Holdings Inc. (FTHM) decreased by 8% to $2.19 [4] - Ventyx Biosciences, Inc. (VTYX) fell by 7% to $2.20 [4] - SciSparc Ltd. (SPRC) decreased by 6% to $4.35 [4] - Lightwave Logic, Inc. (LWLG) fell by 6% to $3.45 [4] - Jasper Therapeutics, Inc. (JSPR) decreased by 6% to $2.43 [4] - StableX Technologies, Inc. (SBLX) fell by 5% to $5.67 [4] - Galecto, Inc. (GLTO) decreased by 5% to $2.70 [4]

Core Viewpoint - Jasper Therapeutics, Inc. has announced a public offering of common stock and warrants to raise approximately $30 million to support the development of briquilimab, a novel antibody therapy targeting mast cell driven diseases [1][3]. Group 1: Offering Details - The offering includes 11,670,707 shares of common stock priced at $2.43 per share, along with common warrants to purchase the same number of shares [1]. - Additionally, the offering includes pre-funded warrants for 675,000 shares, priced at $2.43 minus a nominal exercise price of $0.0001 per share [1][2]. - The gross proceeds from the offering are expected to be around $30 million, before deducting underwriting discounts and commissions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for the advancement of briquilimab's preclinical and clinical development programs, as well as for general corporate purposes, including capital expenditures and working capital [3]. Group 3: Company Overview - Jasper Therapeutics is focused on developing briquilimab as a treatment for chronic mast cell diseases, including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) [7]. - Briquilimab is a targeted aglycosylated monoclonal antibody that inhibits signaling through the KIT receptor, leading to the depletion of mast cells and addressing the inflammatory response in these diseases [7]. - The company is currently conducting clinical studies demonstrating the efficacy and safety of briquilimab in patients with CSU and CIndU [7].

REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, announced today that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of its common ...